Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Publication|Articles|October 15, 2025
Pharmacy Practice in Focus: Oncology
- October 2025
- Volume 7
- Issue 7
Amivantamab for EGFR-Mutated Metastatic Non–Small Cell Lung Cancer
Advertisement
Advertisement
The past decade has witnessed a dramatic shift in the treatment approach for patients with metastatic non–small cell lung cancer (mNSCLC), with the identification and understanding of EGFR mutations paving the way for numerous groundbreaking therapies.1 However, despite these advances, the 5-year overall survival (OS) rate for mNSCLC is still less than 10%.2
Related to this article
Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Accelerated approval for patients who progressed on platinum and immunotherapy brings a new mechanism—and a familiar toxicity profile.
If approved, the combination would be the first chemotherapy-free, Bruton tyrosine kinase inhibitor–based regimen for adults with newly diagnosed mantle cell lymphoma (MCL).
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Advertisement
Advertisement